Stocks of IDEAYA Biosciences Inc. (NASDAQ:IDYA) traded higher last session on Wall Street, down -0.50% to $15.91.
According to the data, IDEAYA Biosciences Inc. (NASDAQ:IDYA) has 7 analysts covering its stock. The consensus rating among analysts is ‘Buy’. IDYA stock price is now -8.24% away from the 50-day moving average and 5.18% away from the 200-day moving average. The market capitalization of the company currently stands at $774.98M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
A total of 1 analysts have issued a hold rating and 5 have given it a buy rating.
With the price target of $25, RBC Capital Mkts recently initiated with Outperform rating for IDEAYA Biosciences Inc. (NASDAQ: IDYA). On December 28, 2022, CapitalOne recently initiated its ‘Overweight’ rating on the stock quoting a target price of $29, while ‘Citigroup’ rates the stock as ‘Buy’.
A total of 1.83% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in IDYA stock. A new stake in IDEAYA Biosciences Inc. shares was purchased by MILLENNIUM MANAGEMENT LLC during the first quarter worth $2,966,000. NORGES BANK invested $2,188,000 in shares of IDYA during the first quarter. In the first quarter, NORDEA INVESTMENT MANAGEMENT AB acquired a new stake in IDEAYA Biosciences Inc. valued at approximately $992,000. STATE OF WISCONSIN INVESTMENT BOARD acquired a new stake in IDYA for approximately $598,000. ACADIAN ASSET MANAGEMENT LLC purchased a new stake in IDYA valued at around $405,000 in the second quarter. In total, there are 176 active investors with 94.00% ownership of the company’s stock.
Tuesday’s opening bell rang with an opening price of $16.14 for IDEAYA Biosciences Inc. (NASDAQ: IDYA). During the past 12 months, IDEAYA Biosciences Inc. has had a low of $8.14 and a high of $19.14. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 11.70, and a quick ratio of 11.70.
According to the Biotechnology Company, earnings per share came in at $0.04, beating analysts’ expectations of -$0.62 by 0.66. This compares to -$0.49 EPS in the same period last year. The company reported revenue of $4.02 million for the quarter, compared to $2.96 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 35.79 percent. For the current quarter, analysts expect IDYA to generate $7M in revenue.
IDEAYA Biosciences Inc.(IDYA) Company Profile
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company’s lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
